南方医科大学学报

南方医科大学学报 ›› 2006, Vol. 26 ›› Issue (02): 222-.

• • 上一篇    下一篇

曲美他嗪对冠心病患者胰岛素抵抗的临床观察

蔡建生； 彭志坚；   

  1. 汕头市第二人民医院心内科； 汕头市第二人民医院心内科 广东汕头515011； 广东汕头515011；
  • 出版日期:2006-02-20 发布日期:2006-02-20

Effect of trimitazidine on insulin resistance in patients with coronary heart disease

CAI Jian-sheng, PENG Zhi-jian Department of Cardiology, Second People’s Hospital of Shantoucity, Shantou 515011, China   

  1. 汕头市第二人民医院心内科； 汕头市第二人民医院心内科 广东汕头515011； 广东汕头515011；
  • Online:2006-02-20 Published:2006-02-20

PDF

1094

摘要： 目的观察曲美他嗪对冠心病患者胰岛素抵抗的影响。方法将119例冠心病患者随机分为A、B两组。两组基本用药相同,B组另给曲美他嗪20mg,3次／d,疗程8周。观察两组患者治疗前后血糖、胰岛素水平及胰岛素敏感指数的变化。结果B组与A组对比,治疗后空腹血胰岛素和服糖后2 h胰岛素降低(P<0．01),胰岛素敏感指数增大(P<0．01)。结论曲美他嗪对冠心病伴胰岛素抵抗有一定的临床疗效。 

Abstract: Objective To evaluate the efficacy of trimetazidine on insulin resistance in patients with coronary heart disease (CHD). Methods A cohort of 119 CHD patients were randomly divided into groups A and B receiving the same basic therapy, and the patients in group B were given additional trimetazidine 20 mg 3 times daily for 8 weeks. Before and after treatment, the changes in blood glucose, insulin levels and insulin sensitivity index were evaluated. Results The patients in group B showed better outcome than those in group A. After 8 weeks’ trimetazidine therapy, the fasting insulin and that at 2 h after oral glucose were decreased (P<0.01), and the insulin sensitivity index was improved (P<0.01). Conclusion Trimetazidine may produce obvious therapeutic effect on insulin resistance in CHD patients. 

中图分类号: